Beam Therapeutics posts a narrower Q4 loss as revenues surge past estimates. It secures $500M financing, extending its cash ...
Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will announce its fourth quarter and full ...
Beam Therapeutics recently announced that it secured a standby license with Kobe University and Bio Palette for key gene-editing patents and confirmed the upcoming resignation of board member Carole ...
Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 13 hot stocks to buy with the highest upside potential. On February 9, ...
Investor's Business Daily on MSN
Beam Therapeutics meets 80-plus relative strength rating benchmark
Beam Therapeutics sees its Relative Strength Rating reach the 80-plus level.
Beam Global's CEO Desmond Wheatley is participating in two prominent investment conferences, enhancing the company's visibility among investors. The engagement offers one-on-one meeting opportunities ...
Charles Schwab Investment Management Inc. boosted its position in Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 3.1% during the 4th quarter, Holdings Channel.com reports. The institutional ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results